AltMountain

Highvista Strategies LLC

Boston, MA · CRD 155759
Hedge fund manager

Highvista Strategies LLC is an SEC-registered investment adviser based in Boston, MA that reports managing 23 hedge funds on Form ADV. It reports $9.1 billion in regulatory assets under management. Its private funds, of all types, hold $7.6 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +25.5% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +99.5% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$9.1 billionForm ADV Item 5.F
Gross assets of private funds
$7.6 billionAll private fund types, Form ADV
Hedge funds managed
2340 private funds in total
Employees
80Form ADV Item 5.A
Registration
SEC-registered adviserCRD 155759
Latest Form ADV
03/31/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+25.5%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+99.5%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$438.6 million147 positions, 2026-06-30
$95$147$199Q3 2024Q1 2025Q3 2025Q1 202613F est. $199S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+22.6%+14.8%
Q1 2026+2.4%-4.6%
Q4 2025+27.1%+2.4%
Q3 2025+18.7%+7.8%
Q2 2025+11.4%+10.4%
Q1 2025-7.6%-4.5%
Q4 2024-4.9%+2.1%
Q3 2024+7.7%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

The 50 largest of 136 share positions ($380,873,154) reported by HighVista Strategies LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 13, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Invesco DB Commdy Indx Trck8.97%
  • Revolution Medicines Inc2.47%
  • Abivax SA2.26%
  • Vaxcyte Inc2.12%
  • Genmab A/s2.12%
  • Relay Therapeutics Inc1.94%
  • Tango Therapeutics Inc1.89%
  • Tarsus Pharmaceuticals Inc1.87%
  • Immunovant Inc1.83%
  • Cogent Biosciences Inc1.77%
StockValue% of 13F portfolioSharesShares vs prior quarter
Invesco DB Commdy Indx Trck$34,169,9328.97%1,057,238Unchanged
Revolution Medicines Inc$9,420,8182.47%45,897-31.48%
Abivax SA$8,620,3842.26%87,057-22.98%
Vaxcyte Inc$8,085,8892.12%142,107-5.10%
Genmab A/s$8,066,0462.12%226,098New
Relay Therapeutics Inc$7,388,3161.94%409,325-19.14%
Tango Therapeutics Inc$7,179,8361.89%287,769+10.65%
Tarsus Pharmaceuticals Inc$7,108,8601.87%90,432+3.87%
Immunovant Inc$6,957,1261.83%205,954-25.88%
Cogent Biosciences Inc$6,725,9621.77%210,055+11.27%
LB Pharmaceuticals Inc$6,670,5981.75%173,804-17.83%
Veradermics Inc$6,574,5451.73%54,232New
Edgewise Therapeutics Inc$6,522,2681.71%160,647+76.54%
Alkermes PLC$6,352,0371.67%156,763-12.55%
Compass Pathways PLC$6,329,2231.66%508,780+37.09%
Viridian Therapeutics Inc$5,613,0401.47%272,610+70.50%
Structure Therapeutics Inc$5,321,9351.40%170,193-13.24%
Nurix Therapeutics Inc$5,240,5271.38%221,026+8.48%
Nvidia Corporation$4,999,6951.31%21,892+0.46%
Tyra Biosciences Inc$4,974,0251.31%227,436+23.09%
Enliven Therapeutics Inc$4,827,8231.27%105,319-23.61%
Talen Energy Corp$4,737,5661.24%15,151+85.95%
Spyre Therapeutics Inc$4,488,3591.18%50,414-35.21%
Amylyx Pharmaceuticals Inc$4,467,2871.17%153,515-60.24%
Definium Therapeutics Inc$4,151,8131.09%109,086-55.09%
Amazon Com Inc$4,047,9401.06%16,247+21.27%
Pharvaris N V$4,002,2401.05%126,174-21.38%
Travere Therapeutics Inc$3,328,9570.87%56,538-34.44%
Vera Therapeutics Inc$3,290,5120.86%101,905-3.78%
Meta Platforms Inc$3,272,0120.86%4,512+288.30%
Micron Technology Inc$3,254,9760.85%3,056+142.54%
Praxis Precision Medicines I$3,230,0320.85%11,091-63.29%
GH Research PLC$3,055,1470.80%130,117-18.05%
Argenx SE$2,994,6760.79%3,123-31.53%
Protagonist Therapeutics Inc$2,952,4910.78%20,956-14.33%
Contineum Therapeutics Inc$2,922,7150.77%217,788New
C4 Therapeutics Inc$2,908,0120.76%873,277-35.22%
Union Pac Corp$2,880,2240.76%10,584New
Dianthus Therapeutics Inc$2,859,8640.75%32,480-36.47%
Insmed Inc$2,854,2990.75%25,007-19.99%
United Airls Hldgs Inc$2,851,4150.75%25,700New
Editas Medicine Inc$2,845,3190.75%1,107,128New
Roblox Corp$2,762,5240.73%65,200New
MBX Biosciences Inc$2,738,0820.72%46,709+301.49%
Avalo Therapeutics Inc$2,708,3970.71%176,673+44.09%
Cullinan Therapeutics Inc$2,669,2890.70%173,895New
Xenon Pharmaceuticals Inc$2,637,0690.69%70,908+100.77%
Ocular Therapeutix Inc$2,579,0450.68%336,251-17.69%
Visa Inc$2,565,9750.67%7,141+19.80%
Celldex Therapeutics Inc New$2,513,2010.66%77,544-10.83%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 24 new positions, 35 sold out, 47 increased, 64 reduced and 1 unchanged.

Number of positions (a count, not dollars)

  • New positions24
  • Increased47
  • Unchanged1
  • Reduced64
  • Sold out35

New positions

StockValueShares
Genmab A/s$8,066,046226,098
Veradermics Inc$6,574,54554,232
Contineum Therapeutics Inc$2,922,715217,788
Union Pac Corp$2,880,22410,584
United Airls Hldgs Inc$2,851,41525,700
Editas Medicine Inc$2,845,3191,107,128
Roblox Corp$2,762,52465,200
Cullinan Therapeutics Inc$2,669,289173,895
First Tracks Biotherapeutics$2,473,21669,786
Flex LTD$1,792,50716,297
Rivian Automotive Inc$1,786,824119,600
Avantor Inc$1,774,395117,900
SPS Comm Inc$1,673,53220,300
Coherent Corp$1,660,6645,770
Delta Air Lines Inc$1,435,51217,200
Cerebras Systems Inc$1,421,2008,000
National Vision Hldgs Inc$1,369,36883,600
Mobility Global Inc$1,359,68679,282
Alto Neuroscience Inc$921,60736,099
Sea LTD$681,5207,000

Sold out

StockValue at Jun 30, 2026Shares held then
Alumis Inc$5,627,100199,968
Mineralys Therapeutics Inc$2,322,57386,085
Eyepoint Inc$2,226,567155,704
RBC Bearings Inc$2,075,8053,223
Rocket Cos Inc$1,977,098125,530
Texas Instrs Inc$1,937,4556,500
KBR Inc$1,871,73354,206
Flowserve Corp$1,850,88624,958
On Semiconductor Corp$1,720,62818,200
Nucor Corp$1,692,9007,600
Qnity Electronics Inc$1,584,1079,700
Knight-swift Transn Hldgs In$1,565,18720,100
Brinks Co$1,550,95916,414
Qxo Inc$1,406,93881,420
US Foods Hldg Corp$1,329,25013,000
Lumentum Hldgs Inc$1,301,6771,517
Firstenergy Corp$1,240,79426,100
Moodys Corp$1,209,2962,670
Applied Matls Inc$1,185,7201,640
Nextera Energy Inc$1,170,67713,338

Largest increases

StockChange in sharesChangeValue nowShares now
Edgewise Therapeutics Inc+69,651+76.54%$6,522,268160,647
Meta Platforms Inc+3,350+288.30%$3,272,0124,512
Viridian Therapeutics Inc+112,725+70.50%$5,613,040272,610
Talen Energy Corp+7,003+85.95%$4,737,56615,151
MBX Biosciences Inc+35,075+301.49%$2,738,08246,709
Amphenol Corp+23,749+410.81%$2,489,37929,530
Micron Technology Inc+1,796+142.54%$3,254,9763,056
Compass Pathways PLC+137,660+37.09%$6,329,223508,780
Xenon Pharmaceuticals Inc+35,590+100.77%$2,637,06970,908
Vistra Corp+9,065+185.00%$1,932,05813,965
Credo Technology Group Holdi+5,800+100.00%$2,259,56411,600
Mirum Pharmaceuticals Inc+11,768+79.02%$2,278,89726,660
Golar LNG LTD+21,100+95.48%$2,052,86443,200
Immunocore Hldgs PLC+32,655+75.62%$2,297,19475,840
Tyra Biosciences Inc+42,662+23.09%$4,974,025227,436
Astera Labs Inc+2,525+78.96%$2,037,2165,723
Western Digital Corp+1,906+62.49%$2,252,3044,956
Avalo Therapeutics Inc+54,063+44.09%$2,708,397176,673
Mastercard Incorporated+1,457+61.12%$2,118,1963,841
Seagate Technology Hldngs PL+843+45.08%$2,502,3082,713

Largest reductions

StockChange in sharesChangeValue nowShares now
Amylyx Pharmaceuticals Inc-232,565-60.24%$4,467,287153,515
Praxis Precision Medicines I-19,119-63.29%$3,230,03211,091
Definium Therapeutics Inc-133,798-55.09%$4,151,813109,086
Revolution Medicines Inc-21,086-31.48%$9,420,81845,897
Cytokinetics Inc-49,425-63.36%$1,883,57628,578
Maze Therapeutics Inc-116,979-85.65%$532,53819,593
Abivax SA-25,974-22.98%$8,620,38487,057
Spyre Therapeutics Inc-27,393-35.21%$4,488,35950,414
Immunovant Inc-71,919-25.88%$6,957,126205,954
Relay Therapeutics Inc-96,910-19.14%$7,388,316409,325
Hewlett Packard Enterprise C-27,370-46.33%$2,026,01631,711
Travere Therapeutics Inc-29,695-34.44%$3,328,95756,538
Dyne Therapeutics Inc-107,114-62.29%$1,044,68564,847
Dianthus Therapeutics Inc-18,645-36.47%$2,859,86432,480
C4 Therapeutics Inc-474,859-35.22%$2,908,012873,277
Axsome Therapeutics Inc.-8,418-41.71%$2,169,34911,765
Enliven Therapeutics Inc-32,547-23.61%$4,827,823105,319
LB Pharmaceuticals Inc-37,707-17.83%$6,670,598173,804
Argenx SE-1,438-31.53%$2,994,6763,123
Liquidia Corporation-41,219-42.10%$1,715,04656,677

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (9)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private equity funds filing Form D (6)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Venture capital funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (37)

Fund
Gross assets
Minimum
Owners
Adviser
Highvista I Limited Partnership
Delaware, United StatesHedge fund
Gross assets$639M
Minimum$5.0M
Owners51
AdviserHighvista Strategies LLC
Highvista (Offshore) LTD.
Cayman IslandsHedge fund
Gross assets$599M
Minimum$5.0M
Owners14
AdviserHighvista Strategies LLC
Highvista 1.5 (Offshore) LTD
Cayman IslandsHedge fund
Gross assets$548M
Minimum$5.0M
Owners1
AdviserHighvista Strategies LLC
Highvista 1.5 (U.S.) LP
Delaware, United StatesHedge fund
Gross assets$276M
Minimum$5.0M
Owners39
AdviserHighvista Strategies LLC
Highvista Designated Portfolio Fr, Limited Partnership
Delaware, United StatesPrivate fund
Gross assets$243M
Minimum$5.0M
Owners1
AdviserHighvista Strategies LLC
Wind River Fund LP
Delaware, United StatesHedge fund
Gross assets$241M
Minimum$5.0M
Owners1
AdviserHighvista Strategies LLC
Highvista Biotechnology Opportunities Fund LP
Delaware, United StatesHedge fund
Gross assets$189M
Minimum$5.0M
Owners28
AdviserHighvista Strategies LLC
Highvista II Limited Partnership
Delaware, United StatesHedge fund
Gross assets$140M
Minimum$5.0M
Owners16
AdviserHighvista Strategies LLC
Highvista Designated Portfolio Ns Limited Partnership
Delaware, United StatesHedge fund
Gross assets$120M
Minimum$5.0M
Owners1
AdviserHighvista Strategies LLC
Highvista Opportunistic Private Credit Fund II LP
Delaware, United StatesHedge fund
Gross assets$119M
Minimum$5.0M
Owners27
AdviserHighvista Strategies LLC
Highvista Credit Portfolio Ls, Limited Partnership
Delaware, United StatesHedge fund
Gross assets$117M
Minimum$5.0M
Owners1
AdviserHighvista Strategies LLC
Highvista Opportunistic Private Credit Fund LP
Delaware, United StatesHedge fund
Gross assets$113M
Minimum$5.0M
Owners28
AdviserHighvista Strategies LLC
Highvista Credit Portfolio Ls II, Limited Partnership
Delaware, United StatesHedge fund
Gross assets$112M
Minimum$5.0M
Owners1
AdviserHighvista Strategies LLC
Highvista III LTD.
Cayman IslandsHedge fund
Gross assets$97.9M
Minimum$5.0M
Owners10
AdviserHighvista Strategies LLC
Highvista PE (Cayman) LTD.
Cayman IslandsPrivate equity fund
Gross assets$28.8M
MinimumNone set
Owners1
AdviserHighvista Strategies LLC
Highvista Strategic Cre Fund LP
Delaware, United StatesHedge fund
Gross assets$27.7M
Minimum$5.0M
Owners7
AdviserHighvista Strategies LLC
Highvista Opportunistic Private Equity Fund I LP
Delaware, United StatesPrivate equity fund
Gross assets$20.3M
Minimum$5.0M
Owners10
AdviserHighvista Strategies LLC
Highvista Dbt Fund I LP
Delaware, United StatesHedge fund
Gross assets$13.8M
Minimum$5.0M
Owners2
AdviserHighvista Strategies LLC
HVS PE Fund Limited Partnership
Delaware, United StatesPrivate equity fund
Gross assets$782K
Minimum$5.0M
Owners1
AdviserHighvista Strategies LLC
TPP II Limited Partnership
Delaware, United StatesPrivate equity fund
Gross assets$0
MinimumNone set
Owners1
AdviserHighvista Strategies LLC
CHVS Master Jv 1 LLC
Delaware, United StatesPrivate equity fund
Gross assets$0
MinimumNone set
Owners3
AdviserHighvista Strategies LLC
Highvista Private Equity Fund I LP
Delaware, United StatesPrivate equity fund
Gross assets$0
MinimumNone set
Owners8
AdviserHighvista Strategies LLC
HVS Eastland Limited Partnership
Delaware, United StatesHedge fund
Gross assets$0
MinimumNone set
Owners3
AdviserHighvista Strategies LLC
HVS Clarendon I LP
Delaware, United StatesHedge fund
Gross assets$0
MinimumNone set
Owners6
AdviserHighvista Strategies LLC
Highvista Biotechnology Master Fund LP
Delaware, United StatesHedge fund
Gross assets$0
Minimum$5.0M
Owners2
AdviserHighvista Strategies LLC
Highvista Evergreen III Limited Partnership
Delaware, United StatesPrivate fund
Gross assets$0
MinimumNone set
Owners7
AdviserHighvista Strategies LLC
Highvista Partners Limited Partnership
Delaware, United StatesHedge fund
Gross assets$0
MinimumNone set
Owners2
AdviserHighvista Strategies LLC
TPP I Limited Partnership
Delaware, United StatesPrivate equity fund
Gross assets$0
MinimumNone set
Owners1
AdviserHighvista Strategies LLC
TPP III Limited Partnership
Delaware, United StatesPrivate equity fund
Gross assets$0
MinimumNone set
Owners3
AdviserHighvista Strategies LLC
HVS Westland Limited Partnership
Delaware, United StatesHedge fund
Gross assets$0
MinimumNone set
Owners3
AdviserHighvista Strategies LLC
HVS III (Aggregate) LP
Cayman IslandsPrivate equity fund
Gross assets$0
MinimumNone set
Owners1
AdviserHighvista Strategies LLC
HVS PE Fund (Cayman) L.P.
Cayman IslandsPrivate equity fund
Gross assets$0
MinimumNone set
Owners2
AdviserHighvista Strategies LLC
HVS Berkeley I LP
Delaware, United StatesPrivate equity fund
Gross assets$0
MinimumNone set
Owners5
AdviserHighvista Strategies LLC
HVS Boylston Limited Partnership
Delaware, United StatesHedge fund
Gross assets$0
MinimumNone set
Owners7
AdviserHighvista Strategies LLC
Highvista Master Fund Limited Partnership
Delaware, United StatesPrivate fund
Gross assets$0
MinimumNone set
Owners8
AdviserHighvista Strategies LLC
Highvista Biotechnology Opportunities Fund LTD
Cayman IslandsHedge fund
Gross assets$0
Minimum$5.0M
Owners0
AdviserHighvista Strategies LLC
Highvista Credit Opportunities Fund I LLC
Delaware, United StatesHedge fund
Gross assets$0
MinimumNone set
Owners7
AdviserHighvista Strategies LLC

As reported in the adviser's Form ADV filed Mar 28, 2024. Funds also listed from Form D are shown above.

Fund vehicles: feeder funds and single-deal vehicles (3)

Fund
Gross assets
Minimum
Owners
Adviser
Highvista Biotechnology Specialist Fund LTD
Cayman IslandsHedge fund
Gross assets$198M
Minimum$5.0M
Owners5
AdviserHighvista Strategies LLC
Highvista Hfs Partners Offshore SPC Portfolio a
Cayman IslandsHedge fund
Gross assets$108M
Minimum$5.0M
Owners6
AdviserHighvista Strategies LLC
Highvista Hfs Limited Partnership
Delaware, United StatesHedge fund
Gross assets$0
Minimum$5.0M
Owners1
AdviserHighvista Strategies LLC

Feeder funds invest through a master fund; single-deal vehicles (SPVs, co-investments, series) hold one investment.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌‌​⁠